From lab-grown mini livers to engineered bile ducts, regenerative medicine is beginning to change how it approaches aging and organ failure.
Liver disease has occupied an uncomfortable place in medicine. It is widespread, often silent for decades and, once advanced, notoriously difficult to reverse. Doctors can slow progression and manage complications, but true repair has remained frustratingly out of reach.
At this year’s European Association for the Study of the Liver (EASL) Congress in Barcelona, however, the conversation felt different. Less about managing decline, more about rebuilding what has been lost.
Researchers presented a series of advances that, taken together, suggest regenerative liver medicine may finally be entering a more practical phase – one where scientists are no longer simply observing liver damage, but actively learning how to reconstruct tissue, prevent scarring and potentially restore function [1].
This week, the World Health Organization (WHO) formally recognized liver disease as a global health priority alongside cancer, cardiovascular disease and diabetes. The scale alone explains why: around 1.5 billion people worldwide are affected by liver conditions. However, there is another reason the field is drawing attention. The liver is deeply tied to longevity itself.
Long before wrinkles or frailty appear, the liver is already working behind the scenes to regulate metabolism, filter toxins, manage inflammation and process nutrients. When it begins to fail, the effects ripple throughout the body. Aging researchers increasingly view liver dysfunction not as an isolated problem, but as part of the wider erosion of resilience that defines biological aging. At EASL 2026, that idea hovered over nearly every discussion.
Building mini livers in the lab
One of the clearest signs of how far science has progressed came from Meritxell Huch of the Max Planck Institute of Molecular Cell Biology and Genetics, whose team has spent years developing liver organoids – tiny three-dimensional structures grown from human cells that mimic some functions of the real organ.
Huch described an organoid as a “miniaturized version of an organ in a dish, that has to grow by self-organization and retain some tissue function and structure.” The concept is relatable. Imagine giving cells the biological equivalent of building instructions and enough support to organize themselves into liver-like tissue. Not a full organ, but something close enough to behave like one in meaningful ways.
To explain how her team recreated the liver’s complexity, Huch compared the process to a self-organizing LEGO system. “We try to expand the different cells independently and then we find the media that allows them to be together and generate a liver,” she said.
The result is what researchers call “assembloids” – combinations of liver cell types that can reproduce key aspects of liver biology, including the scarring processes seen in biliary fibrosis. It represents a major departure from how liver disease has traditionally been studied. For decades, researchers relied heavily on animal models that often failed to mirror what happens in human patients. Organoids offer something closer to a living human system, potentially allowing scientists to test therapies faster and more accurately.
Another important implication: medicine is becoming increasingly personalized. In the future, organoids grown from a patient’s own cells could help predict how someone might respond to a drug before treatment even begins.
The hidden complexity of alcohol-related liver disease
Another recurring theme at EASL was complexity – particularly around alcohol-associated liver disease (ALD), which researchers are beginning to understand less as a single illness and more as a constantly evolving process.
Una Rastovic of King’s College London described ALD as “not one disease but more a dynamic spectrum of clinical manifestations and a moving target.” Public conversations about liver disease often reduce it to a simple cause-and-effect story, but biologically, the picture is messier. The liver adapts to damage for years before it begins to fail, cycling through inflammation, repair attempts and structural remodeling.
To study those changes more realistically, researchers are now using precision-cut liver slices – thin sections of human liver tissue kept alive outside the body. These slices allow scientists to observe how real human tissue responds to stress, including prolonged alcohol exposure.
The team also explored the effects of rencofilstat, a drug that appeared to reduce fibrosis, the gradual stiffening and scarring that prevents the liver from functioning properly.
One particularly striking area of research focused on mitochondria, the tiny energy-producing structures inside cells. Researchers observed visible changes in mitochondrial size and shape after alcohol exposure, offering another reminder that aging and chronic disease often begin at the cellular level long before symptoms appear.
Engineering replacement bile ducts
Perhaps the most ambitious work unveiled at EASL came from researchers at the University of Cambridge, who are attempting something that once sounded almost implausible: bioengineering replacement bile ducts.
Liver transplantation remains the only definitive treatment for many end-stage liver diseases, but donor organs are scarce and waiting lists remain long.
“Bioengineering promises to address all these challenges,” said Fotios Sampaziotis, co-founder of Bilitech Ltd, a Cambridge spin-out focused on regenerative therapies.
The process begins with pig bile ducts. Researchers remove the living cells entirely, leaving behind a biological scaffold, essentially the structural framework of the tissue. Human organoid cells are then placed onto that scaffold to create functional bile ducts. Think of it like renovating an abandoned building while preserving its architecture. The challenge, however, was fibrosis. Scar tissue repeatedly formed after transplantation, threatening to block the ducts.
Researchers ultimately turned to sirolimus, an already approved drug, but delivered it in a highly targeted way. Instead of exposing the entire body to the medication long term, they engineered bile ducts capable of slowly releasing the drug during the critical healing period after transplant.
The results in pigs were surprisingly durable. Six months later, animals had developed no strictures, despite the drug itself disappearing within weeks.
“It seems there is a critical window of opportunity that results in long-lasting effects, preventing fibrosis even 6 months down the line,” explained Teresa Brevini.
That insight may end up extending beyond liver disease. Across regenerative medicine, scientists are increasingly discovering that timing matters just as much as treatment itself. The body appears to have narrow windows where intervention can redirect healing away from chronic scarring and toward functional repair.
Longevity investors are watching
The commercial world is already taking notice. According to data from Decoding Longevity Trends (DLT), companies with liver-related programs have collectively attracted billions in investment.
Biogen leads the field with $10.79 billion raised, followed by Alnylam Pharmaceuticals at $7.54 billion and Arrowhead Pharmaceuticals at $5.70 billion. The broader ecosystem now includes regenerative medicine startups, RNA therapeutics companies and organoid-focused biotech firms all converging on liver biology.
The enthusiasm reflects something larger than hepatology alone. For longevity researchers, the liver is emerging as one of the most compelling proving grounds for regenerative medicine. If scientists can learn to reverse fibrosis, regenerate tissue and restore organ function here, similar strategies could eventually be applied across aging organs throughout the body.
EASL 2026 did not deliver a miracle cure. Much of the work remains experimental and significant hurdles still lie ahead. However, for the first time, the field feels less focused on slowing deterioration and more focused on rebuilding health itself. That is a subtle difference, but potentially a transformative one.
